Evidence map›Paper›PMID 37119286›Full record

ReviewArchives of virology2023

B lymphocytes in COVID-19: a tale of harmony and discordance.

Amir Hossein Mansourabadi, Azin Aghamajidi, Maryam Dorfaki, Fatemeh Keshavarz, Zahra Shafeghat, Ali Moazzeni, Fahimeh Lavi Arab, Arezoo Rajabian, Mona Roozbehani, Reza Falak and 2 more

Abstract readReview
In one paragraph

Review in Archives of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. SARS-CoV-2 Chronic Intervillositis: Variations of Maternal Antiviral Response.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. B Cell Dynamics and Transitional B Cells in Long COVID.Current issues in molecular biology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. The effect of COVID-19 and sex differences on natural killer cell cytotoxicity.Frontiers in cellular and infection microbiology · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amir Hossein MansourabadiDepartment of Immunology, School of medicine, Tehran University of Medical Sciences, Tehran, Iran.
Azin AghamajidiDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Maryam DorfakiDepartment of Microbiology and Immunology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Fatemeh KeshavarzCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Zahra ShafeghatDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ali MoazzeniBlood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization (IBTO), Tehran, Iran.
Fahimeh Lavi ArabDepartment of Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Arezoo RajabianDepartment of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mona RoozbehaniVaccine Research Center, Iran University of Medical Sciences, Tehran, Iran.
Reza FalakDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fatemeh FarajiImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran. faraji.fat@iums.ac.ir.ORCID http://orcid.org/0000-0002-1761-7969
Reza JafariCellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran. Jafari.reza@umsu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B lymphocytes play a vital role in the human defense against viral infections by producing specific antibodies. They are also critical for the prevention of infectious diseases by vaccination, and their activation influences the efficacy of the vaccination. Since the beginning of coronavirus disease 2019 (COVID-19), which became the main concern of the world health system, many efforts have been made to treat and prevent the disease. However, for the development of successful therapeutics and vaccines, it is necessary to understand the interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and the immune system. The innate immune system provides primary and nonspecific defense against the virus, but within several days after infection, a virus-specific immune response is provided first by antibody-producing B cells, which are converted after the resolution of disease to memory B cells, which provide long-term immunity. Although a failure in B cell activation or B cell dysfunction can cause a severe form of the disease and also lead to vaccination inefficiency, some individuals with B cell immunodeficiency have shown less production of the cytokine IL-6, resulting in a better disease outcome. In this review, we present the latest findings on the interaction between SARS-CoV-2 and B lymphocytes during COVID-19 infection.

Indexed as

COVID-19Antibodies, ViralB-LymphocytesCytokinesHumansSARS-CoV-2VaccinationAntibodies, ViralCytokinesB cell immune responseB lymphocyteCOVID-19SARS-CoV-2

Identifiers

PMID37119286
PMCPMC10147999

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.